Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer - Abstract

Department of Urology, Keio University School of Medicine, Tokyo, Japan.


There are still few effective therapeutic options for advanced prostate cancer. One of the most troublesome aspects of prostate cancer is that androgen dependent prostate cancer inevitably progresses to highly aggressive, life threatening castration resistant prostate cancer after androgen ablation therapy. To our knowledge it remains unknown how sensitivity to docetaxel changes during progression to more aggressive castration resistant prostate cancer under androgen ablation.

We investigated sensitivity to docetaxel and phosphorylated Akt status in C4-2 and C4-2AT6 cells established at our institution.

C4-2AT6 cells established under androgen ablation conditions for 6 months showed significantly higher resistance to docetaxel than C4-2 cells in vivo and in vitro. Resistance was accompanied by increased phosphorylated Akt. In C4-2AT6 cells phosphorylated Akt activity was significantly up-regulated by docetaxel in a dose dependent manner. After treatment with docetaxel and a phosphatidylinositol 3-kinase/Akt inhibitor the sensitivity of C4-2AT6 cells to docetaxel markedly increased through enhanced apoptotic death.

Findings indicated that up-regulation of phosphorylated Akt during androgen ablation and its further activation by docetaxel explains at least in part the resistance to docetaxel and progression to castration resistant prostate cancer under androgen ablation conditions.

Written by:
Kosaka T, Miyajima A, Shirotake S, Suzuki E, Kikuchi E, Oya M.   Are you the author?

Reference: J Urol. 2011 Apr 19. Epub ahead of print.
doi: 10.1016/j.juro.2011.02.016

PubMed Abstract
PMID: 21511293

UroToday.com Prostate Cancer Section